Delivery Order SPE2DB24D9222-SPE2DB24FAZHA

Award Date 9/17/24
Potential Completion Date 10/8/24
Potential Value $1.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,949.98 firm fixed-price delivery order is for the supply of LUCENTIS 0.5 MG/0.05ML, a pharmaceutical product, with a period of performance through September 26, 2024. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,071.52 firm fixed-price delivery order is for LUCENTIS 0.3 MG/0.05 ML SYRING 0.05ML, with a performance period ending on August 23, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,088.88 contract will provide LUCENTIS 0.5 MG/0.05 ML SYRING 0.05ML medical supplies to support the recurring pharmaceutical needs of military health facilities under the DLA's Medical Supply Chain division. This delivery order is part of a larger $499,999,999 indefinite delivery...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $1,544.44, is for the supply of the pharmaceutical product Lucentis 0.5 mg/0.05 ml syringe 0.05 ml. DMS Pharmaceutical Group holds a significant single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $3,861.10, is for the delivery of LUCENTIS 0.5 MG/0.05 ML SYRING 0.05ML, a pharmaceutical product. The contract is a firm fixed-price delivery order with a performance period through May 29, 2024. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract (IDC) with the...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $1,544.44, is for the delivery of Lucentis 0.5 mg/0.05 ml syringes to support the medical supply needs of military health facilities. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group, valued up to...
This federal contract award is for LUCENTIS 0.5 MG/0.05 ML SYRING 0.05ML, awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order with a ceiling value of $14,033.28 and an ultimate completion date of July 19, 2022. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at...
The Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the purchase of LUCENTIS 0.3 MG/0.05 ML SYRING 0.05ML. The contract has a completion date of February 16, 2024 and a potential value of $15,178.80. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler based in Park Ridge, Illinois that provides a wide range of branded and generic prescription drugs, medical supplies, and other...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,444.40 firm fixed-price delivery order contract is for the purchase of the drug Lucentis 0.5 mg/0.05 ml syringe. This award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which allows the DLA to issue...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $1,155.24 contract is for the supply of Lucentis 0.3 mg/0.05 ml syringes to fulfill the recurring pharmaceutical needs of military health facilities. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs...
  • SPE2DB24D9222
    Indefinite Delivery Contract
  • SPE2DB24D9222-SPE2DB24FAZHA
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,544.44 firm fixed-price delivery order is for the supply of LUCENTIS 0.5 MG/0.05 ML syringes, with a completion date of October 8, 2024.

DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This single-award IDC allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health facilities worldwide. Through this vehicle, DMS Pharmaceutical Group provides both routine and critical medications to support the diverse medical needs of military personnel and their dependents across various Department of Defense healthcare facilities.

Generated 12/17/24, 9:36 AM